Novo Nordisk reported DKK31.44B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025